OOIR: Observatory of International Research

Papers

(The H4-Index of mAbs is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Correction	306
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	245
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	163
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	137
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	134
In silico prediction of post-translational modifications in therapeutic antibodies	103
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	103
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	102
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	79
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	79
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	77
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics	73
Correction	72
An antibody developability triaging pipeline exploiting protein language models	71
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	70
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	68
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	68
Correction	58
Structural and functional characterization of a monoclonal antibody blocking TIGIT	57
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	53
Antibodies to watch in 2024	51
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	48
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	47
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	43
The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	41

GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	41
Predicting antibody binders and generating synthetic antibodies using deep learning	41
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	41
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs	40
Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection	39
A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology	39
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	38
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	36
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	35
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	34
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	34
Impact of IgG subclass on monoclonal antibody developability	34